A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose,
dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts:
a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part
2 will include an initial dose escalation portion followed by a dose expansion portion.
Approximately 142 adult patients are expected to be enrolled in the study.

Inclusion Criteria:

- Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy;
or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is
available..

- Adequate Bone Marrow Function.

- Adequate Renal & Liver Function.

- Adequate Performance Status

Exclusion Criteria:

- Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring
steroids.

- Previous high-dose chemotherapy requiring allogenic stem cell rescue.

- Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.